Sabaa International for Pharmaceutical and Chemical Industry (SIPC) turned profitable at EGP 11.933 million in the first half (H1) of 2025, compared to net losses valued at EGP 11.443 million in H1 2024
Updated 8/18/2025 11:00:00 AM
Sabaa International for Pharmaceutical and Chemical Industry (SIPC) incurred net losses after tax of EGP 1.019 million during the first quarter (Q1) of 2024, up by 940.49% from EGP 98,021 in the year-ago quarter.
Updated 6/2/2024 9:28:00 AM
Sabaa International for Pharmaceutical and Chemical Industry’s (SIPC) net profits after tax soared 1,396.3% year on year (YoY) in 2023 to EGP 271,121, compared to EGP 18,119.
Updated 3/27/2024 10:28:00 AMSabaa International for Pharmaceutical and Chemical Industry (SIPC) incurred net losses after tax of EGP 3.881 million during the first nine months of 2023, versus net profits after tax amounting to EGP 488,979 during the same period in 2022.
Updated 11/12/2023 10:55:00 AM
Sabaa is an Egypt-based company engaged in the pharmaceutical sector. The company’s generic product portfolio includes products focused on different therapeutic categories.
Updated 8/14/2023 9:30:00 AM
Sabaa is an Egypt-based company engaged in the pharmaceutical sector. The company’s generic product portfolio includes products focused on different therapeutic categories.
Updated 5/31/2023 11:23:00 AM
Saba International is an Egypt-based company operating in the pharmaceutical sector, with a generic product portfolio that includes products focused on different therapeutic categories.
Updated 3/27/2023 11:10:00 AM